Holen Sie sich die Stockscreener-App
14.28
20.00%
-3.57
Schlusskurs vom Vortag:
$17.85
Offen:
$15.03
24-Stunden-Volumen:
4.63M
Relative Volume:
3.02
Marktkapitalisierung:
$1.65B
Einnahmen:
$674.41M
Nettoeinkommen (Verlust:
$-173.05M
KGV:
-9.3072
EPS:
-1.5343
Netto-Cashflow:
$-48.07M
1W Leistung:
-19.37%
1M Leistung:
-18.21%
6M Leistung:
+13.69%
1J Leistung:
-15.00%
1-Tages-Spanne:
$13.88
$15.10
1-Wochen-Bereich:
$13.88
$18.35
52-Wochen-Spanne:
$9.82
$18.92
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
14.28 | 1.65B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
NovoCure (NVCR) Is Down 19.7% After TRIDENT Misses Survival Endpoint In Earlier TTFields Use - simplywall.st
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Barchart.com
Novocure (NVCR) Experiences Significant Decline in Stock Price - GuruFocus
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result - simplywall.st
NVCR Reiterated by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Novocure’s Optune Gio fails to show benefit at earlier stage - Yahoo Finance
Novocure TRIDENT trial misses primary endpoint - grafa.com
Novocure (NVCR) Reports TRIDENT Trial Results for Glioblastoma T - GuruFocus
Novocure Announces Topline Phase 3 TRIDENT Trial Data for TTFields Therapy in Newly Diagnosed Glioblastoma Patients – Minichart - Minichart
Novocure (NVCR) Faces 20% Drop After Phase 3 Trial Setback - GuruFocus
Novocure (NVCR) Sees Significant Decline in Stock Price - GuruFocus
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - Benzinga
Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal - Yahoo Finance
Novocure device fails to improve brain cancer patients’ survival in phase 3 test - Fierce Biotech
Why is Novocure stock plummeting today? By Investing.com - Investing.com Australia
FreeCast surges premarket; Accenture, Novocure slide - Investing.com
FreeCast surges premarket; Accenture, Novocure slide By Investing.com - Investing.com India
Novocure’s glioblastoma trial fails primary endpoint - Investing.com
Novocure’s glioblastoma trial fails primary endpoint By Investing.com - Investing.com Canada
Novocure stock tumbles after trial misses primary endpoint By Investing.com - Investing.com South Africa
Novocure (NASDAQ: NVCR) Phase 3 TRIDENT glioblastoma study misses survival endpoint - Stock Titan
Novocure's glioblastoma trial shows survival data, but no primary win - Stock Titan
Novocure Ltd (NVCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Novocure Ltd (NVCR) Institutional Confidence - TradingKey
Novocure Ltd (NVCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Novocure Ltd (NVCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Novocure Ltd (NVCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Novocure Ltd (NVCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Novocure Ltd (NVCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Novocure Ltd (NVCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Novocure Ltd (NVCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
NovoCure (NVCR) Appoints Frank Leonard To Its Board After Shareholder Vote - simplywall.st
NovoCure Ltd stock (JE00B6T5S470): Focus on Tumor Treating Fields technology as investors weigh rece - AD HOC NEWS
Frank Leonard’s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR) - Yahoo Finance
Have Insiders Sold NovoCure Shares Recently? - simplywall.st
NovoCure Limited Adopts Amended and Restated 2024 Omnibus Incentive Plan and Reports 2026 Annual Meeting Results - Minichart
Novocure Insider Sold Shares Worth $614,635, According to a Recent SEC Filing - marketscreener.com
NovoCure Limited Elects Frank Leonard as Director, Effective June 3, 2026 - marketscreener.com
NovoCure (NASDAQ: NVCR) investors OK directors and tight 2024 incentive plan vote - Stock Titan
NovoCure (NVCR) CEO sells 34,273 shares in tax-related transaction - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and options in new equity awards - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and options in 2026 award - Stock Titan
NovoCure (NVCR) director receives new share and stock option awards - Stock Titan
NovoCure (NVCR) grants RSUs and stock options to director Scannell - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and 16,999 stock options - Stock Titan
[Form 4] NovoCure Ltd Insider Trading Activity - Stock Titan
NovoCure (NASDAQ: NVCR) awards director new RSUs and stock options - Stock Titan
NovoCure (NASDAQ: NVCR) grants RSUs and stock options to director Vernon W. Anthony - Stock Titan
NovoCure Ltd stock (JE00B6T5S470): shares jump after double-digit move puts focus on valuation - AD HOC NEWS
Is It Too Late to Buy NovoCure Ltd (NVCR) After 11.4% Rally? GF Value Says Undervalued - GuruFocus
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):